WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that it will host a conference call and live webcast Wednesday to discuss its financial results for the fourth quarter and full year ended December 31, 2025, and provide a corporate update.
The company said the call is scheduled for 8:30 a.m. Eastern Time on March 11.
Participants may join the call by telephone using domestic or international dial-in numbers and a conference identification code provided by the company. Verrica also said a live audio webcast will be available through the investor relations section of its website at www.verrica.com.
A replay of the webcast will remain available on the company’s website for 90 days after the event.
Verrica Pharmaceuticals develops treatments for skin diseases requiring medical intervention.
Its product YCANTH (VP-102), a cantharidin-based therapy, is approved by the U.S. Food and Drug Administration for the treatment of molluscum contagiosum in adults and children age two and older. Molluscum contagiosum is a contagious viral skin infection affecting an estimated 6 million people in the United States, primarily children.
YCANTH is also being studied as a treatment for common warts.
The company has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (ruxotemitide), a treatment candidate being studied for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.